Loading…

Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy

PURPOSE: Metastatic renal cell carcinoma (RCC) is one of the most treatment-resistant malignancies and nephrectomy, isolated or combined with systemic chemotherapy typically has limited or no effectiveness. We report our initial results in patients treated with the association of molecular targeted...

Full description

Saved in:
Bibliographic Details
Published in:International Brazilian journal of urology 2011-04, Vol.37 (2), p.180-186
Main Authors: Dall'Oglio, Marcos F., Sousa-Canavez, Juliana M., Tanno, Fabio Y., Tiseo, Bruno C., Crippa, Alexandre, Reis, Sabrina T. dos, Leite, Katia R. M., Srougi, Miguel
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c434t-427bc05e050ac1c99fbdae850a494ee8dda0191991a8791b085c3212b6e85b2f3
cites cdi_FETCH-LOGICAL-c434t-427bc05e050ac1c99fbdae850a494ee8dda0191991a8791b085c3212b6e85b2f3
container_end_page 186
container_issue 2
container_start_page 180
container_title International Brazilian journal of urology
container_volume 37
creator Dall'Oglio, Marcos F.
Sousa-Canavez, Juliana M.
Tanno, Fabio Y.
Tiseo, Bruno C.
Crippa, Alexandre
Reis, Sabrina T. dos
Leite, Katia R. M.
Srougi, Miguel
description PURPOSE: Metastatic renal cell carcinoma (RCC) is one of the most treatment-resistant malignancies and nephrectomy, isolated or combined with systemic chemotherapy typically has limited or no effectiveness. We report our initial results in patients treated with the association of molecular targeted therapy, nephrectomy, and hybrid dendritic-tumor cell (DC) vaccine. MATERIALS AND METHODS: Two male patients diagnosed with metastatic RCC were selected for the study. They were treated with the triple strategy, in which sunitinib (50 mg per day) was given for 4 weeks, followed by radical nephrectomy after two weeks. DC vaccine was initiated immediately after surgery and repeated monthly. Sunitinib was restarted daily after 2 to 3 weeks of surgery with a 7-day interval every 4 weeks. RESULTS: Both patients had complete adherence to the proposed treatment with DC vaccine therapy combined with sunitinib. Follow-up in these patients at 9 and 10 months demonstrated a stable disease in both, as shown by imaging and clinical findings, with no further treatment required. CONCLUSION: The immune response obtained with DC vaccine combined with the antiangiogenic effect of sunitinib and the potential benefits of cytoreductive nephrectomy in advanced disease could represent a new option in the treatment of metastatic RCC. Further prospective trials are needed not only to elucidate the ideal dosing and schedule, but also to better define the proof-of-concept proposed in this report and its role in clinical practice.
doi_str_mv 10.1590/S1677-55382011000200004
format article
fullrecord <record><control><sourceid>doaj_cross</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_704a0ae72d0c440c8d83203c6561c8b0</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_704a0ae72d0c440c8d83203c6561c8b0</doaj_id><sourcerecordid>oai_doaj_org_article_704a0ae72d0c440c8d83203c6561c8b0</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-427bc05e050ac1c99fbdae850a494ee8dda0191991a8791b085c3212b6e85b2f3</originalsourceid><addsrcrecordid>eNplkd1Kw0AQhYMoWKvP4L5AdDbZJLuXUqoWCl6o12EyO2lT8sdmqebtTVspghfD_JyPw8AJgnsJDzIx8Pgu0ywLkyTWEUgJANFUoC6C2Vm4_DNfBzfDsJsoA5mcBfslunoU_N2zq7glFl-V3wqPbsOerfBbdtiPAlsrLLfWVb4iQVzXYo9EVcuiakXDHgePB8lxi_UJIHQT0DUosPTsRMv91jH5rhlvg6sS64Hvfvs8-Hxefixew_Xby2rxtA5JxcqHKsoKgoQhASRJxpSFRdbTpoxi1tYiSCONkagzIwvQCcWRjIp0goqojOfB6uRrO9zlvasadGPeYZUfD53b5Oimt2vOM1AIyFlkgZQC0lbHEcSUJqkkXcDklZ28yHXD4Lg8-0nID1Hkxyjyf1HEP6_8fdg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy</title><source>SciELO</source><creator>Dall'Oglio, Marcos F. ; Sousa-Canavez, Juliana M. ; Tanno, Fabio Y. ; Tiseo, Bruno C. ; Crippa, Alexandre ; Reis, Sabrina T. dos ; Leite, Katia R. M. ; Srougi, Miguel</creator><creatorcontrib>Dall'Oglio, Marcos F. ; Sousa-Canavez, Juliana M. ; Tanno, Fabio Y. ; Tiseo, Bruno C. ; Crippa, Alexandre ; Reis, Sabrina T. dos ; Leite, Katia R. M. ; Srougi, Miguel</creatorcontrib><description>PURPOSE: Metastatic renal cell carcinoma (RCC) is one of the most treatment-resistant malignancies and nephrectomy, isolated or combined with systemic chemotherapy typically has limited or no effectiveness. We report our initial results in patients treated with the association of molecular targeted therapy, nephrectomy, and hybrid dendritic-tumor cell (DC) vaccine. MATERIALS AND METHODS: Two male patients diagnosed with metastatic RCC were selected for the study. They were treated with the triple strategy, in which sunitinib (50 mg per day) was given for 4 weeks, followed by radical nephrectomy after two weeks. DC vaccine was initiated immediately after surgery and repeated monthly. Sunitinib was restarted daily after 2 to 3 weeks of surgery with a 7-day interval every 4 weeks. RESULTS: Both patients had complete adherence to the proposed treatment with DC vaccine therapy combined with sunitinib. Follow-up in these patients at 9 and 10 months demonstrated a stable disease in both, as shown by imaging and clinical findings, with no further treatment required. CONCLUSION: The immune response obtained with DC vaccine combined with the antiangiogenic effect of sunitinib and the potential benefits of cytoreductive nephrectomy in advanced disease could represent a new option in the treatment of metastatic RCC. Further prospective trials are needed not only to elucidate the ideal dosing and schedule, but also to better define the proof-of-concept proposed in this report and its role in clinical practice.</description><identifier>ISSN: 1677-5538</identifier><identifier>EISSN: 1677-5538</identifier><identifier>EISSN: 1677-6119</identifier><identifier>DOI: 10.1590/S1677-55382011000200004</identifier><language>eng</language><publisher>Sociedade Brasileira de Urologia</publisher><subject>dendritic cells ; neoplasm metastasis ; renal cell carcinoma</subject><ispartof>International Brazilian journal of urology, 2011-04, Vol.37 (2), p.180-186</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-427bc05e050ac1c99fbdae850a494ee8dda0191991a8791b085c3212b6e85b2f3</citedby><cites>FETCH-LOGICAL-c434t-427bc05e050ac1c99fbdae850a494ee8dda0191991a8791b085c3212b6e85b2f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Dall'Oglio, Marcos F.</creatorcontrib><creatorcontrib>Sousa-Canavez, Juliana M.</creatorcontrib><creatorcontrib>Tanno, Fabio Y.</creatorcontrib><creatorcontrib>Tiseo, Bruno C.</creatorcontrib><creatorcontrib>Crippa, Alexandre</creatorcontrib><creatorcontrib>Reis, Sabrina T. dos</creatorcontrib><creatorcontrib>Leite, Katia R. M.</creatorcontrib><creatorcontrib>Srougi, Miguel</creatorcontrib><title>Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy</title><title>International Brazilian journal of urology</title><description>PURPOSE: Metastatic renal cell carcinoma (RCC) is one of the most treatment-resistant malignancies and nephrectomy, isolated or combined with systemic chemotherapy typically has limited or no effectiveness. We report our initial results in patients treated with the association of molecular targeted therapy, nephrectomy, and hybrid dendritic-tumor cell (DC) vaccine. MATERIALS AND METHODS: Two male patients diagnosed with metastatic RCC were selected for the study. They were treated with the triple strategy, in which sunitinib (50 mg per day) was given for 4 weeks, followed by radical nephrectomy after two weeks. DC vaccine was initiated immediately after surgery and repeated monthly. Sunitinib was restarted daily after 2 to 3 weeks of surgery with a 7-day interval every 4 weeks. RESULTS: Both patients had complete adherence to the proposed treatment with DC vaccine therapy combined with sunitinib. Follow-up in these patients at 9 and 10 months demonstrated a stable disease in both, as shown by imaging and clinical findings, with no further treatment required. CONCLUSION: The immune response obtained with DC vaccine combined with the antiangiogenic effect of sunitinib and the potential benefits of cytoreductive nephrectomy in advanced disease could represent a new option in the treatment of metastatic RCC. Further prospective trials are needed not only to elucidate the ideal dosing and schedule, but also to better define the proof-of-concept proposed in this report and its role in clinical practice.</description><subject>dendritic cells</subject><subject>neoplasm metastasis</subject><subject>renal cell carcinoma</subject><issn>1677-5538</issn><issn>1677-5538</issn><issn>1677-6119</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNplkd1Kw0AQhYMoWKvP4L5AdDbZJLuXUqoWCl6o12EyO2lT8sdmqebtTVspghfD_JyPw8AJgnsJDzIx8Pgu0ywLkyTWEUgJANFUoC6C2Vm4_DNfBzfDsJsoA5mcBfslunoU_N2zq7glFl-V3wqPbsOerfBbdtiPAlsrLLfWVb4iQVzXYo9EVcuiakXDHgePB8lxi_UJIHQT0DUosPTsRMv91jH5rhlvg6sS64Hvfvs8-Hxefixew_Xby2rxtA5JxcqHKsoKgoQhASRJxpSFRdbTpoxi1tYiSCONkagzIwvQCcWRjIp0goqojOfB6uRrO9zlvasadGPeYZUfD53b5Oimt2vOM1AIyFlkgZQC0lbHEcSUJqkkXcDklZ28yHXD4Lg8-0nID1Hkxyjyf1HEP6_8fdg</recordid><startdate>20110401</startdate><enddate>20110401</enddate><creator>Dall'Oglio, Marcos F.</creator><creator>Sousa-Canavez, Juliana M.</creator><creator>Tanno, Fabio Y.</creator><creator>Tiseo, Bruno C.</creator><creator>Crippa, Alexandre</creator><creator>Reis, Sabrina T. dos</creator><creator>Leite, Katia R. M.</creator><creator>Srougi, Miguel</creator><general>Sociedade Brasileira de Urologia</general><scope>AAYXX</scope><scope>CITATION</scope><scope>DOA</scope></search><sort><creationdate>20110401</creationdate><title>Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy</title><author>Dall'Oglio, Marcos F. ; Sousa-Canavez, Juliana M. ; Tanno, Fabio Y. ; Tiseo, Bruno C. ; Crippa, Alexandre ; Reis, Sabrina T. dos ; Leite, Katia R. M. ; Srougi, Miguel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-427bc05e050ac1c99fbdae850a494ee8dda0191991a8791b085c3212b6e85b2f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>dendritic cells</topic><topic>neoplasm metastasis</topic><topic>renal cell carcinoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dall'Oglio, Marcos F.</creatorcontrib><creatorcontrib>Sousa-Canavez, Juliana M.</creatorcontrib><creatorcontrib>Tanno, Fabio Y.</creatorcontrib><creatorcontrib>Tiseo, Bruno C.</creatorcontrib><creatorcontrib>Crippa, Alexandre</creatorcontrib><creatorcontrib>Reis, Sabrina T. dos</creatorcontrib><creatorcontrib>Leite, Katia R. M.</creatorcontrib><creatorcontrib>Srougi, Miguel</creatorcontrib><collection>CrossRef</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International Brazilian journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dall'Oglio, Marcos F.</au><au>Sousa-Canavez, Juliana M.</au><au>Tanno, Fabio Y.</au><au>Tiseo, Bruno C.</au><au>Crippa, Alexandre</au><au>Reis, Sabrina T. dos</au><au>Leite, Katia R. M.</au><au>Srougi, Miguel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy</atitle><jtitle>International Brazilian journal of urology</jtitle><date>2011-04-01</date><risdate>2011</risdate><volume>37</volume><issue>2</issue><spage>180</spage><epage>186</epage><pages>180-186</pages><issn>1677-5538</issn><eissn>1677-5538</eissn><eissn>1677-6119</eissn><abstract>PURPOSE: Metastatic renal cell carcinoma (RCC) is one of the most treatment-resistant malignancies and nephrectomy, isolated or combined with systemic chemotherapy typically has limited or no effectiveness. We report our initial results in patients treated with the association of molecular targeted therapy, nephrectomy, and hybrid dendritic-tumor cell (DC) vaccine. MATERIALS AND METHODS: Two male patients diagnosed with metastatic RCC were selected for the study. They were treated with the triple strategy, in which sunitinib (50 mg per day) was given for 4 weeks, followed by radical nephrectomy after two weeks. DC vaccine was initiated immediately after surgery and repeated monthly. Sunitinib was restarted daily after 2 to 3 weeks of surgery with a 7-day interval every 4 weeks. RESULTS: Both patients had complete adherence to the proposed treatment with DC vaccine therapy combined with sunitinib. Follow-up in these patients at 9 and 10 months demonstrated a stable disease in both, as shown by imaging and clinical findings, with no further treatment required. CONCLUSION: The immune response obtained with DC vaccine combined with the antiangiogenic effect of sunitinib and the potential benefits of cytoreductive nephrectomy in advanced disease could represent a new option in the treatment of metastatic RCC. Further prospective trials are needed not only to elucidate the ideal dosing and schedule, but also to better define the proof-of-concept proposed in this report and its role in clinical practice.</abstract><pub>Sociedade Brasileira de Urologia</pub><doi>10.1590/S1677-55382011000200004</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1677-5538
ispartof International Brazilian journal of urology, 2011-04, Vol.37 (2), p.180-186
issn 1677-5538
1677-5538
1677-6119
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_704a0ae72d0c440c8d83203c6561c8b0
source SciELO
subjects dendritic cells
neoplasm metastasis
renal cell carcinoma
title Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T13%3A44%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-doaj_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20experience%20with%20targeted%20therapy%20and%20dendritic%20cell%20vaccine%20in%20metastatic%20renal%20cell%20carcinoma%20after%20nephrectomy&rft.jtitle=International%20Brazilian%20journal%20of%20urology&rft.au=Dall'Oglio,%20Marcos%20F.&rft.date=2011-04-01&rft.volume=37&rft.issue=2&rft.spage=180&rft.epage=186&rft.pages=180-186&rft.issn=1677-5538&rft.eissn=1677-5538&rft_id=info:doi/10.1590/S1677-55382011000200004&rft_dat=%3Cdoaj_cross%3Eoai_doaj_org_article_704a0ae72d0c440c8d83203c6561c8b0%3C/doaj_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c434t-427bc05e050ac1c99fbdae850a494ee8dda0191991a8791b085c3212b6e85b2f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true